Anlon Healthcare IPO Sees Overwhelming Response; Issue Subscribed 7.12x on Final Day

New Delhi, August 29, 2025 — The ₹121 crore initial public offering (IPO) of Anlon Healthcare Limited (Symbol: AHCL) closed today with a grand overall subscription of 7.12 times, indicating robust demand across investor categories.

Anlon Healthcare Limited, founded in 2013, produces Active Pharmaceutical Ingredients (APIs), advanced intermediates, nutraceutical compounds, and personal care/veterinary ingredients. Its WHO-GMP, GMP, and ISO 9001:2015 certified facility at Rajkot, Gujarat, commenced commercial production in 2017.

With a portfolio of more than 65 products, the firm serves therapeutic classes like anti-inflammatories, analgesics, antipyretics, antidepressants, and nutrition. In terms of finances, Anlon’s top line expanded from ₹6,669.19 lakh in FY24 to ₹12,045.51 lakh in FY25, with net profit moving up to ₹2,051.79 lakh in FY25.

Final Subscription Status (as of August 29, 2025, 5:00 PM IST)

The company’s IPO closed with robust demand across categories, with an overall subscription of 7.12 times. The Qualified Institutional Buyers (QIBs) segment was subscribed 1.07 times, whereas Non-Institutional Investors (NIIs) placed strong bids at 10.61 times. In the NII segment, applications of over ₹10 lakh were subscribed 7.56 times, while bids in the ₹2–10 lakh band witnessed an astonishing 16.69 times subscription. The Retail Individual Investors (RIIs) response was best, with the category being oversubscribed 47.26 times. A total of, in comparison to 1.33 crore shares offered, more than 9.47 crore shares were bid for at the end of the bidding on August 29, 2025, 5:00 PM IST.

Price-Wise Bidding Trend

The trend in bidding indicates that investor interest continued to remain firm at all price levels. At the top price level of ₹91, investors bid for approximately 9.44 crore shares, with rising demand at every lower price level, up to 9.48 crore shares at ₹86. The number of bids at the cut-off price was 5.20 crore shares, indicating high overall demand for the issue at both higher and lower price brackets.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations